O-(quinolin-6-ylmethyl)hydroxylamine | 205111-42-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: O-(quinolin-6-ylmethyl)hydroxylamine
• 英文别名: o-[(Quinolin-6-yl)methyl]hydroxylamine
• CAS: 205111-42-8
• 化学式: C₁₀H₁₀N₂O
• 分子量: 174.202
• InChiKey: QPRCBNIMYBRNKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• 6-0 substituted ketolides having antibacterial activity
  申请人：ABBOTT LABORATORIES

  公开号：EP1291350A1

  公开（公告）日：2003-03-12

  Antimicrobial compounds having the formula (IV-A) as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

  具有式（IV-A）的抗菌化合物及其药学上可接受的盐、酯或原药；包含此类化合物的药物组合物；通过施用此类化合物治疗细菌感染的方法；以及制备此类化合物的工艺。
• 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY
  申请人：Abbott Laboratories

  公开号：EP0929563B1

  公开（公告）日：2005-06-01
• 6-O-substituted ketolides having antibacterial activity
  申请人：ABBOTT LABORATORIES

  公开号：EP1291352B1

  公开（公告）日：2005-05-25
• IDO INHIBITORS
  申请人：Newlink Genetics

  公开号：EP2227233A2

  公开（公告）日：2010-09-15